MONJUVI
NDC 73535-208, Tafasitamab-cxix, injection, powder, lyophilized, for solution, from Incyte Corporation.
- Product NDC
- 73535-208
- Status
- Listed
- Labeler
- Incyte Corporation
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- BLA
- Application
- BLA761163
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/73535-208 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- TAFASITAMAB200 mg/5mL
| Package NDC | NDC-11 | Package |
|---|---|---|
| 73535-208-01 | 73535020801 | 1 VIAL in 1 CARTON (73535-208-01) / 5 mL in 1 VIAL |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/ec13ac6b-bfde-4e84-907a-83bd69584d95Medicare Part B payment limits (ASP)
GET /v1/drugs/asp?ndc=73535-208
Use it
Look up 73535-208 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/73535-208 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 73535-208. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.